Key Highlights

  • Cardinal Health ranked among the weakest S&P 500 stocks on Friday, with no company-specific news found, a day after jumping to $229.05 on news it extended its CVS Health distribution deal through June 30, 2032.
  • Rivals McKesson and Cencora also slipped Friday, placing all three major US drug wholesalers among the index's laggards as health care became the only one of 11 S&P 500 sectors to finish lower.
  • Cardinal reaffirmed its fiscal 2027 adjusted Earnings outlook of $12.40 to $12.60 per share alongside the Thursday CVS news, while health care added 17,000 jobs in September, led by ambulatory care and hospitals.
  • The broader market rallied on a weak jobs report that cut Federal Reserve rate-hike odds, pulling investor attention toward growth names like Tesla and Nvidia and away from defensive businesses such as drug distribution.

Cardinal Health (NYSE:CAH) fell on Friday, ranking among the weakest stocks in the S&P 500 a day after it rallied on news that it had locked in a major customer for years to come. The Ohio-based company is one of America's three big pharmaceutical wholesalers. It buys medicines from drugmakers and delivers them to pharmacies, hospitals and clinics, earning a thin Margin on enormous volumes. No company-specific news on Cardinal was found for Friday. The decline came after a strong Thursday, and no new development was identified to explain the move.

Thursday's CVS Boost

On October 1, Cardinal Health and rival McKesson both announced they had extended their distribution agreements with CVS Health through June 30, 2032. For a wholesaler, a contract with one of the country's largest pharmacy chains is a cornerstone of revenue, and the news was well received.

Cardinal shares jumped to $229.05 that day. Cardinal also reaffirmed its fiscal 2027 adjusted earnings outlook of $12.40 to $12.60 per share, while McKesson reaffirmed its own guidance of $44.20 to $45 per share. CVS stock rose too, closing at $86.89.

On Friday, much of that enthusiasm faded. McKesson and Cencora, the third major distributor, also slipped, placing all three on the list of the S&P 500's weakest names.

Health Care Stood Alone in the Red

The distributors' slide fit a broader pattern. Ten of the 11 S&P 500 sectors rose on Friday, and health care was the only one to finish lower, if only barely. Veeva Systems, Boston Scientific and Alnylam were also among the sector's laggards.

The rest of the market had a very different day. A weak September jobs report showed employers added only 29,000 jobs, far short of forecasts around 84,000. That cut expectations for another Federal Reserve rate hike at the October 27-28 meeting, with odds dropping to roughly one in five from about two in three earlier in the week.

Investors used that relief to pile into technology and growth stocks. Tesla, Nvidia and a wide range of chipmakers led the charge, and the Nasdaq-100 closed at a record 30,807.93. The S&P 500 added 56.27 points to 7,722.72.

Defensive businesses such as drug distribution tend to attract money when investors are nervous and lose some appeal when traders chase growth. Friday was firmly a growth day.

Jobs Data With a Health Care Twist

Interestingly, health care was one of the few bright spots in the jobs report itself. The sector added 17,000 positions in September, led by ambulatory care and hospitals. That underlines the steady Demand that supports wholesalers like Cardinal, even when the stocks take a breather.

Treasury yields, after falling on the jobs news, reversed and closed higher, with the 10-year finishing near its highest level since 2002.

The CVS Extension Gives a Clear Benchmark

The key question is whether Friday's pullback was simple profit-taking or the start of a longer pause. The CVS extensions run through mid-2032, giving the distributors visibility on a major customer for several years.

Investors will also watch the Fed's October 27-28 meeting and the start of earnings season, which kicks off with PepsiCo on October 8 and the big banks on October 13 and 14. Analysts expect strong double-digit earnings growth for the S&P 500 in the third quarter. For Cardinal, the reaffirmed fiscal 2027 outlook of $12.40 to $12.60 per share remains the benchmark the market will measure it against.